



Public Citizen
Attn. P. Maybarduk
1600 20th Street, NW
Washington, D.C. 20009
USA

15 May 2014

Dear Mr Maybarduk,

We would like to thank you for your letter dated April 8, 2014, sent to Professor Barner, the Chairman of the BMD of Boehringer Ingelheim.

We are pleased to say that we also welcome the Medicines Patent Pool – ViiV Healthcare Licensing Agreement.

Boehringer Ingelheim after some time is in the final stage of negotiations with the MPP with the aim to include our non-assert declaration (NAD) policy into the MPP strategy.

On the NAD, the Boehringer Ingelheim Policy Paper on HIV/AIDS states:

Expanded Access - ARV Patent Policy for the developing world

In order to substantially extend access to the active ingredient Nevirapine, Boehringer Ingelheim in May 2007 decided to not enforce its patents and offers interested manufactures listed on the WHO pre-qualification programme (or being FDA approved) non-assert declarations enabling them at no additional costs to supply Nevirapine-containing medicines for eligible countries.

These eligible countries are defined as all low income countries according to the World Bank classification of economies, all countries classified as Least Developed Country (LDC) according to the United Nations Development Programme and all African states which are not classified as low income of LDC.

We hope this information proves helpful.

Sincerely yours,


Ingrid Herzog

Our reference
IH

Dr. Ingrid Herzog
Phone +49 6132 77-144393
Fax +49 6132 77-2602
E-Mail ingrid.herzog@boehringer-ingelheim.com

Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Phone +49 6132 77-0
Fax +49 6132 72-0
www.boehringer-ingelheim.com

Board of Managing Directors
Prof. Dr Dr Andreas Barner
(Chairman)
Dr Wolfgang Baiker
Hubertus von Baumbach
Dr Joachim Hasenmaier
Allan Hillgrove

Chairman of the
Supervisory Board
Christian Boehringer

Registered Office
Ingelheim am Rhein
Commercial Register Mainz
HR B 21005

Deutsche Bank AG
BIC: DEUTDE5MXXX
IBAN:
DE82 5507 0040 0024 7650 00